American Water Works Company Inc vs Bristol-Myers Squibb Co — how do they compare? American Water Works Company Inc trades at $131.69 (market cap $25.69B), while Bristol-Myers Squibb Co trades at $57.13 (market cap $121.18B). The key difference: Bristol-Myers Squibb Co is far larger — about 4.7× American Water Works Company Inc's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.25%). Which is the better fit depends on your goals.
| AWK | BMY | |
|---|---|---|
Market Cap | $25.69B | $121.18B |
Sector | Utilities | Health |
52-Week High | $147.00 | $62.37 |
52-Week Low | $121.13 | $42.60 |
Enterprise Value | $41.25B | $157.12B |
Dividend Yield | 2.72% | 4.25% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Trailing returns across standard periods
Latest headlines on both assets
American Water Works is the largest investor-owned U.S. water and wastewater utility, serving approximately 3.5 million customers in 16 states. It provides water and wastewater services to residential, commercial, and industrial customers and operates predominantly in regulated markets. The company's only nonregulated business is water services for military bases, which operates under long-term contracts.
Read more on AWK →Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →